| 203 | 3 | 91 |
| 下载次数 | 被引频次 | 阅读次数 |
子宫内膜异位症(简称内异症)是育龄期妇女常见的妇科疾病，其累及病变广泛、临床表现多样，且具有侵袭性、复发性及性激素依赖等特点。内异症的临床表现主要有疼痛、月经失调、不孕、盆腔肿物等，当前其治疗原则主要依据患者的症状、年龄、生育要求、病情程度选择合适的治疗方法，腹腔镜手术是内异症的首选治疗方案，但也有术后复发率较高、盆腹腔微小病灶难以彻底清除等风险，因此需术后联合药物治疗(如口服米非司酮、口服地屈孕酮或皮下注射促性腺激素释放激素激动剂等)进行长期管理，从而减少复发。育龄期内异症患者以控制疼痛、保护和促进生育为主，孕激素为首选药物。本例患者28岁，属于育龄期女性，有生育要求，主要诉求为缓解痛经及控制内膜异位囊肿发展，术后继续使用地屈孕酮进行长期管理，痛经得到明显缓解，在短时间内成功妊娠并分娩。
Abstract：[1] Zondervan KT,Becker CM,Missmer SA.Endometriosis[J].N Engl J Med,2020,382:1244-1256.
[2] 郎景和.对子宫内膜异位症认识的历史、现状与发展[J].中国实用妇科与产科杂志，2020,36:193-196.
[3] Merboth MK,Bamaion S.Managing pain:the fifth vital sign[J].Nuts Clin North Am,2000,35:375-383.
[4] Melzack R,Torgerson WS.On the language of pain[J].Anesthesiology,1971,34:50-59.
[5] Melzack R.The short- form McGill pain questionnaire[J].Pain,1987,30:191-197.
[6] Melzack R.The McGill pain questionnaire:major properties and scoring methods[J].Pain,1975,1:277-299.
[7] Yen CF,Kim MR,Lee CL.Epidemiologic factors associated with endometriosis in East Asia[J].Gynecol Minim Invasive Ther,2019,8:4-11.
[8] Practice Committee of the American Society for Reproductive Medicine.Endometriosis and infertility:a committee opinion[J].Fertil Steril,2012,98:1400-1406.
[9] Laganà AS,Garzon S,G?tte M,et al.The pathogenesis of endometriosis:molecular and cell biology insights[J].Int J Mol Sci,2019,20:5615.
[10] Yong PJ,Matwani S,Bracr C,et al.Endometriosis and ectopic pregnancy:a meta-analysis[J].J Minim Invasive Gynecol,2020,27:352-361.e2.
[11] Breteau P,Chanavaz-Lacheray I,Rubod C,et al.Pregnancy rates after surgical treatment of deep infiltrating endometriosis in infertile patients with at least 2 previous in vitro fertilization or intracytoplasmic sperm injection failures[J].J Minim Invasive Gynecol,2020,27:1148-1157.
[12] Agarwal SK,Chapron C,Giudice LC,et al.Clinical diagnosis of endometriosis:a call to action[J].Am J Obstet Gynecol,2019,220:354.
[13] Zakhari A,Delpero E,McKeown S,et al.Endometriosis recurrence following post-operative hormonal suppression:a systematic review and meta-analysis[J].Hum Reprod Update,2021,27:96-107.
[14] 都君君.深部浸润型子宫内膜异位症的药物治疗[J].中国实用医药，2016,11:188-189.
[15] Becker CM,Bokor A,Heikinheimo O,et al.ESHRE guideline:endometriosis[J].Hum Reprod Open,2022,2022:hoac009.
[16] 复方口服避孕药临床应用中国专家共识专家组.复方口服避孕药临床应用中国专家共识[J].中华妇产科杂志，2015,50:81-91.
[17] Schweppe KW.The ranking of the gestagens in the treatment of pain caused by endometriosis-an overview[J].Zentrallol Genakol,2003,125:276-280.
[18] Vercellini P,Frontino G,De Giorigi O,et al.Endometriosis Preoperative and postoperative medical treatment[J].Obstet Gynecol Clin North Am,2003,30:163-180.
[19] Griesinger G,Tournaye H,Macklon N,et al.Dydrogesterone:pharmacological profile and mechanism of action as luteal phase support in assisted preproduction[J/OL].Reprod Biomed Online,2019,38:249-259.
[20] 彭超，周应芳.药物治疗在子宫内膜异位症长期管理中的应用和选择[J].中国实用妇科与产科杂志，2021,37:303-308.
[21] Taniguchi F,Ota I,Iba Y,et al.The efficacy and safety of dydrogesterone for treatment of dysmenorrhea:an open-label multicenter clinical study[J].J Obstet Gynaecol Res,2019,45:168-175.
[22] 仰少君，支云清.地屈孕酮治疗痛经的临床效果观察[J].临床药物治疗杂志，2017,15:39-42.
[23] Trivedi P,Selvaraj K,Mahapatra PD,et al.Effective post-laparoscopic treatment of endometriosis with dydrogesterone[J].Gynecol Endocrinol,2007,23(Suppl 1):73-76.
[24] Kitawaki J,Koga K,Kanzo T,et al.An assessment of the efficacy and safety of dydrogesterone in women with ovarian endomtrioma:an open-label multicenter clinical study[J].Reprod Med Biol,2021,20:345-351.
[25] Sukhikh GT,Adamyan LV,Dubrovina SO,et al.Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis:results of the ORCHIDEA study[J].Fertil Steril,2021,116:1568-1577.
基本信息:
中图分类号:R711.71
引用信息:
[1]朱云珊,王晓茜,孙晓彤,等.有生育要求子宫内膜异位症患者术后地屈孕酮后半周期治疗后妊娠：1例报告并文献复习[J].生殖医学杂志,2024,33(02):247-251.
2024-02-15
2024-02-15